RxDoctor Payments Data

Jason Mizell, MD

Colon & Rectal Surgery · Little Rock, ARNPI 1639107394

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,000 of the $3,591 with a category attached, or 83.5%. Applied Medical Resources Corporation accounts for 83.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $3,012 and has fallen 93.7% since, to $191 in 2025.

$3,591in general payments, 2019–2025

Across 14 payments — averaging $256.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Applied Medical Resources Corporation$3K
  • W. L. Gore & Associates, Inc.$171
  • Braintree Laboratories, Inc.$164
  • TELA Bio, Inc.$117
  • Johnson & Johnson$48
  • Medtronic$34
  • plus $57 from 2 others

What the payments were for

  • Speaking & faculty fees$3,00084%
  • Food & beverage$42712%
  • Gifts$1645%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few colon & rectal surgery providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$130,886
Medicare patients
222
Services billed
655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,579
Methocarbamol11$80
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$70
Gabapentin19$61
Oxycodone Hcl25$58
Metronidazole32$37
Ciprofloxacin Hcl30$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$164$2,57916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few colon & rectal surgery providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other colon & rectal surgery in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →